Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 20/20 | 0.80 |
| ▸ | MAP2K2 | P36507 | 11/20 | 0.80 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.80 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.80 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.80 |
| ▸ | ADCK1 | Q86TW2 | 1/20 | 0.80 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.80 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 0.47 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL388196 | 1.00 | MAP2K1 (0.80) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL387163 | 1.00 | MAP2K1 (0.80) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL13942040 | 0.92 | MAP2K1 (0.79) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL391896 | 0.92 | MAP2K1 (0.79) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL391682 | 0.91 | MAP2K1 (0.78) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL18088595 | 0.90 | MAP2K1 (0.66) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL391551 | 0.89 | MAP2K1 (0.73) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL389794 | 0.89 | MAP2K1 (0.73) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL389793 | 0.89 | MAP2K1 (0.73) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| Refametinib SCHEMBL345334 | 0.89 | MAP2K1 (1.00) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130261120-A1 | SUBSTITUTED N-(2-ARYLAMINO)ARYL SULFONAMIDE-CONTAINING COMBINATIONS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-10-03 | — | — | US | claimed |
| EP-2621486-A1 | SUBSTITUTED N-(2-ARYLAMINO)ARYL SULFONAMIDE-CONTAINING COMBINATIONS | Bayer Intellectual Property GmbH (DE) | 2013-08-07 | — | — | EP | claimed |
| US-20130184270-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE-CONTAINING COMBINATIONS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-18 | — | — | US | claimed |
| EP-2558126-A2 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE-CONTAINING COMBINATIONS | Bayer Intellectual Property GmbH (DE) | 2013-02-20 | — | — | EP | claimed |
| WO-2012041987-A1 | SUBSTITUTED N-(2-ARYLAMINO)ARYL SULFONAMIDE-CONTAINING COMBINATIONS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-04-05 | — | — | WO | claimed |
| WO-2011128407-A2 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE-CONTAINING COMBINATIONS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-10-20 | — | — | WO | claimed |
| US-20170183333-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK | ARDEA BIOSCIENCES, INC. (US) | 2017-06-29 | — | — | US | disclosed |
| US-20170183333-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK | ARDEA BIOSCIENCES, INC. (US) | 2017-06-29 | — | — | US | disclosed |
| US-20170183333-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK | ARDEA BIOSCIENCES, INC. (US) | 2017-06-29 | — | — | US | disclosed |
| EP-2175885-B1 | COMBINATIONS OF MEK INHIBITORS AND RAF KINASE INHIBITORS AND USES THEREOF | ARDEA BIOSCIENCES INC (US) | 2016-10-12 | — | — | EP | disclosed |
| US-20160271122-A1 | COMBINATIONS OF MEK INHIBITORS AND RAF KINASE INHIBITORS AND USES THEREOF | ARDEA BIOSCIENCES, INC. (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160271122-A1 | COMBINATIONS OF MEK INHIBITORS AND RAF KINASE INHIBITORS AND USES THEREOF | ARDEA BIOSCIENCES, INC. (US) | 2016-09-22 | — | — | US | disclosed |
| US-9381177-B2 | Substituted N-(2-arylamino)aryl sulfonamide-containing combinations | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-07-05 | — | — | US | disclosed |
| US-20090082457-A1 | (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide; MEK kinase (mitogen-activated ERK-activating kinases, MAP kinase kinase); cancer, tumors, autoimmune disorders, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis | ANDREA BIOSCIENCES, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| WO-2009018238-A1 | COMBINATIONS OF MEK INHIBITORS AND RAF KINASE INHIBITORS AND USES THEREOF | ARDEA BIOSCIENCES, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| EP-1912636-A2 | N-(ARYLAMINO)-SULFONAMIDE INHIBITORS OF MEK | Ardea Biosciences, Inc. (US) | 2008-04-23 | — | — | EP | disclosed |
| US-20080058340-A1 | MEK kinase (mitogen-activated ERK-activating kinases or MAP kinase kinase); cancer, tumors, infections, autoimmune disorders, stroke, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis; 1-sulfonamido-2-(phenylamino)-4-fluorobenzene compounds | ARDEA BIOSCIENCES, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-20080058340-A1 | MEK kinase (mitogen-activated ERK-activating kinases or MAP kinase kinase); cancer, tumors, infections, autoimmune disorders, stroke, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis; 1-sulfonamido-2-(phenylamino)-4-fluorobenzene compounds | ARDEA BIOSCIENCES, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-20080058340-A1 | MEK kinase (mitogen-activated ERK-activating kinases or MAP kinase kinase); cancer, tumors, infections, autoimmune disorders, stroke, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis; 1-sulfonamido-2-(phenylamino)-4-fluorobenzene compounds | ARDEA BIOSCIENCES, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| WO-2007014011-A2 | N-(ARYLAMINO)-SULFONAMIDE INHIBITORS OF MEK | ARDEA BIOSCIENCES, INC. (US) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058340-A1 | MEK kinase (mitogen-activated ERK-activating kinases or MAP kinase kinase); cancer, tumors, infections, autoimmune disorders, stroke, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis; 1-sulfonamido-2-(phenylamino)-4-fluorobenzene compounds | BRAF, MAPK1, MAPK12 | MAP2K1 32/4885MAP2K2 23/4885CHEK1 391/4885 |
| US-20170183333-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK | BRAF, NRAS, MAP3K2 | MAP2K1 52/4885MAP2K2 48/4885CHEK1 260/4885 |
| US-20130184270-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE-CONTAINING COMBINATIONS | KIT, CSNK2A1, CSNK1A1 | MAP2K1 27/4885MAP2K2 32/4885CHEK1 68/4885 |
| US-20130261120-A1 | SUBSTITUTED N-(2-ARYLAMINO)ARYL SULFONAMIDE-CONTAINING COMBINATIONS | KIT, CHUK, IKBKB | MAP2K1 358/4885MAP2K2 408/4885CHEK1 1052/4885 |
| US-20160271122-A1 | COMBINATIONS OF MEK INHIBITORS AND RAF KINASE INHIBITORS AND USES THEREOF | BRAF, RAF1, NRAS | MAP2K1 71/4885MAP2K2 74/4885CHEK1 164/4885 |
| US-20090082457-A1 | (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide; MEK kinase (mitogen-activated ERK-activating kinases, MAP kinase kinase); cancer, tumors, autoimmune disorders, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis | BRAF, MAPK1, MAP2K2 | MAP2K1 7/4885MAP2K2 3/4885CHEK1 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.